Experts say the coronavirus will be around well into the future. And that means so will the need for vaccines. In this Motley Fool Live video recorded on May 28, healthcare and cannabis bureau editor and analyst Olivia Zitkus and contributor Adria Cimino discuss what we may expect from coronavirus vaccine makers in three to five years.

10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of May 11, 2021


Olivia Zitkus: With all that in mind, what do you think the landscape of vaccines might look like in three years or in five years? Do you think we're still going to have a lot of options to choose from? I guess we don't even know if we will need all those options. We still have yet to figure that out and for experts to tell us. But what do you think about the outlook for few years or five years?

Adria Cimino: I think there'll be a few market leaders not just one, because clearly one company couldn't serve all of the countries. So there's going to have to be a few out there. We'll also know more about annual revenue. We'll know is this going to be something that is going to keep growing? Is it going to stabilize and plateau and then just stay at a certain level? We'll have -- and this is like three years out. We should have ideas about these things. Some of the players might drop out. Some of the farther behind players might decide, wait a minute, let's just move on to other things because our candidate just isn't working. So there might be fewer players in the end. Farther down the road, talking five years out, I'd say there'll be a lot of innovation. Just looking at the flu vaccine. There's already flu vaccines out there. But like Novavax (NVAX 2.06%) has a flu vaccine candidate that is close to market. It met all primary endpoints in the clinical trial. So that didn't stop them from developing a flu vaccine. There are a lot of companies that could be developing better vaccines well into the future. One thing that we definitely look for is a combined flu and COVID vaccine. That's something that Novavax is working on, Moderna (MRNA -0.58%) is also working on and that's something that will probably be about five years out. We can imagine that coming out.